Innovent Biologics reports Phase 2 clinical data for IBI354 in breast cancer
Innovent Biologics has unveiled Phase 2 trial results for its HER2-targeting ADC, IBI354, during the 2026 ESMO congress.
Innovent Biologics presented clinical data from its Phase 2 trial of IBI354 at the 2026 ESMO congress. The drug, an antibody-drug conjugate (ADC) targeting the HER2 protein, is being studied as a first-line treatment option for patients diagnosed with breast cancer.
The trial results provide preliminary evidence regarding the efficacy and safety profile of IBI354 in a previously untreated patient population. The focus on HER2-targeting therapies reflects a competitive landscape in oncology, where developers aim to refine delivery mechanisms for cytotoxic agents.
These findings represent a progress point in the company's research pipeline. Innovent will use the data to inform the design of future clinical development strategies.